(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Thus, there are now several chronic canine myocardial infarction ventricular tachyarrhythmia models which are available for the evaluation of new antiarrhythmic drugs (Table I). The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model (Table 11). The sustained arrhythmias initiated in these models using programmed pacing presumably have the same localized reentrant mechanism that characterizes chronic human myocardial infarction and chronic coronary 26 artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneous ly-occurring PVCs. In addition, these models are of unproven value in the study of acute spontaneously occurring sudden death; although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use in chronic coronary artery disease patients at risk for sustained reentrant ventricular tachycardia or VF. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricu lar tachyarrhythmias (Table Ill). Therefore, increased use of these chronic models for new antiarrhythmic drug testing is strongly recommended. TABLE II Ideal vs Available Chronic Canine - Arrhythmia Models Ideal Available 1. (a) Arrhythmia mechanism comparable to Yes patients with chronic CAD: Reentry (b) Pathophysiology similar (e. g. , atherogenic CAD) No 2. Susceptible to: (a) spontaneous PVCs No l No (b) spontaneous VT/VF (c) inducible VT/VF Yes 3.
Contents:
How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- Pre-Clinical Evaluation of a New Antiarrhythmic Agent.- Relationships between effects on cardiac electrophysiology and antiarrhythmic efficacy.- What animal models should be used to define antiarrhythmic efficacy: acute dog models?.- Description of chronic canine myocardial infaction models suitable for the electropharmacologic evaluation of new antiarrhythmic drugs.- Non-canine animal models for evaluating antiarrhythmic efficacy General Group Discussion: Animal Models.- Defining the pharmacodynamics and pharmacokinetics of new antiarrhythmic drugs General Group Discussion: Pharmacology.- Chronic Studies in Patients with Non-Hemodynamically Significant Ventricular Arrhythmics.- How should Holter monitoring analysis be performed?.- Long-term ambulatory electrocardiographic recording in the determination of efficacy of new antiarrhythmic agents.- Evaluation of antiarrhythmic drugs. Should the Lown classification be used as a measure of efficacy?.- General Group Discussion: Holter Monitoring.- Study Designs: Chronic Patients.- New means of evaluating antiarrhythmic drugs.- Parallel or crossover designs in evaluation of antiarrhythmic therapy.- General Group Discussion: Study Designs: Chronic Patients.- Remarks: J. Richard Crout, Director, Bureau of Drugs Food and Drug Administration.- Acute Studies in Patients with Hemodynamically Significant Significant Ventricular Arrhythmias.- Acute drug testing as a part of a systematic approach to antiarrhythmic drug therapy.- What is the role of electrophysiology in drug testing? General Group Discussion: Electrophysiology.- What should the study design be to test new antiarrhythmic drugs in patients with acute myocardial infarction, digitalis toxicity and other acute problems General Group Discussion: Study Designs in Acute Patients.- Special Considerations.- What baseline electrophysiologic data should be obtained (plus discussion).- Assessment of the hemodynamic and inotropic effects of antiarrhythmic drugs (plus discussion).- Evaluation of drug treatment in supraventricular arrhythmias (plus discussion).- How should long-term safety of a new antiarrhythmic drug be defined (plus discussion).- How should one manage emergency drug requests and their data (puls discussion).- How does one evaluate and use outside U.S.A. data in the new drug application (plus discussion).
PRODUCT DETAILS
Publisher: Springer
Publication date: November, 2011
Pages: 340
Weight: 522g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
Jean-Claude Tardif
Xander H T Wehrens
Johan H. C. Reiber
Raimund Erbel
M.P. Sambhi
Pedro Brugada
W. Bleifeld
Naranjan S. Dhalla
Bohuslav Ostadal
Ralph Shabetai
Jason X.-J. Yuan
Hein J.J. Wellens
R. C. Becker
Franz H. Messerli
C.H. Peels
Stephen M. Factor
Hiroyuki Suga
Hugo Ector
Brian E. Jaski
Richard A. Walsh
Seymour Glagov
Michiel J. Janse
Lloyd W. Klein
Thomas H Marwick
Ernst E. van der Wall
P.J. Walter
Ernst E. van der Wall
Ernst E. van der Wall
A-M. Salmasi
Michel Emile Safar
A-M. Salmasi
Ernst E. van der Wall
Andrea Natale
Albert de Roos
C.A. Nienaber
Guillem Pons-Llado
Vinzenz Hombach
R. Vos
J. Candell-Riera
R.W. Stout
Peter Hanrath
Johan H. C. Reiber
P.A.F.M. Doevendans
Jack Rychik
P.A.F.M. Doevendans
P.E. Vardas
Makoto Nagano
George D. Dangas
Myrvin H. Ellestad
C.J. Preusse
Thomas H Marwick
Thomas H Marwick
Ernst E. van der Wall
G.T. Meester
A.G. Herman
J.C. Tardif
P.J. Walter
Johan H. C. Reiber
Ernst E. van der Wall
Lloyd W. Klein
Akira Matsumori
Robert L. Wilensky
Bernard Swynghedauw
Juan Carlos Kaski
Franz H. Messerli
John F. Keaney Jr.
Keith L. March
Naranjan S. Dhalla
Zainul Abedin
Juan Carlos Kaski
Eric J Topol
A.V. Bruschke
Richard C. Becker
J. Candell-Riera
Ghassan Bkaily
Lionel H. Opie
Bernard Swynghedauw
Geoffrey Burnstock
P. Cummins
Nicholas Sperelakis
Mina Rajskina
A.A. Knowlton
Johan H. C. Reiber
Irene D. Turpie
J. A. E. Spaan
Ernst E. van der Wall
Masatsugu Hori
Bing Liem Liong
R. Fagard
M. Iwase
R. Stroobandt
A.V. Bruschke
David M. Mirvis
Franz H. Messerli
G. Assmann
Melvin Scheinman
J. Morganroth
J.W. de Jong
M.B. Rosenbaum
C. Tissa Kappagoda
H.V. Villareal
Ernst E. van der Wall
Naranjan S. Dhalla
H. Mitchell Perry Jr.
M.P. Spencer
Henk Keurs
C.T. Lancée
J.R. Roelandt
G.S. Wagner
H. Kesteloot
A.C. Arntzenius
Johan H. C. Reiber
A. Maseri
Michel Emile Safar
M.P. Spencer
W. Bleifeld
Henk Keurs
Willem H. Birkenhager
Antonio Bayes de Luna
J.R. Roelandt
Naranjan S. Dhalla
H. Rijsterborgh
Marianne J. Legato
Naranjan S. Dhalla
S. Chien
Rafael Beyar
H.E. Van Dam
M.P. Spencer
J.R. Roelandt
Hilbert J.Th. Thalen
C. Marchesi
J.P.M Hamer
Rafael Beyar
L.N. Bouman
A. Alboni
Douglas P. Zipes
Nicholas Sperelakis
Borys Surawicz
Antonio Bayes de Luna
Johan H. C. Reiber
Hein J.J. Wellens
J.V. Chapman
E. Aliot
Vinzenz Hombach
Michael R. Rosen
William H. Gaasch
Pawan K. Singal
Robert Plonsey
H.L. Stone
J. Soler-Soler
Ernst E. van der Wall
Michel Emile Safar
J. Morganroth
Hein J.J. Wellens
J.R. Roelandt
Vinzenz Hombach
Richard S. Meltzer
Marvin A. Konstam
Naranjan S. Dhalla
Naranjan S. Dhalla
S.N. Willich
Johan H. C. Reiber
C.A. Nienaber
Ernst E. van der Wall
Robert J. Siegel
Markus Schwaiger
Andrew Wechsler
Elliot Rapaport
Naranjan S. Dhalla
John E. Tooke
Derek Yellon
Henk Keurs
Steve M. Teague
J.W. de Jong
Naranjan S. Dhalla
Nicholas Sperelakis
P.H. Heintzen
J. Morganroth
John B. Lombardini
Adam Schneeweiss
J.R. Roelandt
Naranjan S. Dhalla
Naranjan S. Dhalla
J.C. Chatham
Pim J. de Feyter
David W. Holt
Catherine A. Neill
J. Roelandt
A.P. Shepherd
Gastone Leonetti
Nico H.J. Pijls
K. Robinson
P.A.F.M. Doevendans
Douglas P. Zipes
Jose Marin-Garcia
Jonathan S. Steinberg
Francisco Villarreal
Dick Macdonald
Ragavendra R. Baliga
Dick Macdonald